Enhanced Curcumin Compositions and Methods for NK3 Antagonism

Improved curcumin compositions and methods for NK3 antagonism, enhancing bioavailability, solubility, and stability, and providing targeted and sustained delivery to treat NK3 receptor-mediated disorders.

The original patent identified curcumin compositions as NK3 antagonists, but limitations included poor bioavailability, solubility, and stability. The new inventive concept addresses these limitations by enhancing bioavailability, improving solubility and stability, and providing targeted and sustained delivery.

The inventive concept comprises methods and compositions that enhance the NK3 antagonistic properties of curcumin. New formulations improve bioavailability by at least 20%, and nanoparticle carriers target the central nervous system, releasing curcumin in a sustained manner over 24 hours. Combinations of diferuloylmethane and tetrahydrocurcumin in a 3:2 ratio exhibit improved solubility and stability. Pharmaceutical formulations with optimized excipients further enhance oral bioavailability by at least 30%. These improvements enable effective treatment of NK3 receptor-mediated disorders and prevention of neurokinin-B-induced inflammation.

The new inventive concept introduces novel formulations, delivery systems, and pharmaceutical formulations that significantly improve the performance of curcumin as an NK3 antagonist, overcoming the limitations of the original patent.

Alternative embodiments may include varying the ratio of diferuloylmethane to tetrahydrocurcumin, using different nanoparticle carriers or excipients, or combining curcumin with other NK3 antagonists. Variations may also include different routes of administration, such as injectable or transdermal delivery.

The enhanced curcumin compositions and methods have significant commercial potential in treating NK3 receptor-mediated disorders, such as neurological and psychiatric conditions, and may also be used in the prevention of neurokinin-B-induced inflammation. Target industries include pharmaceutical, nutraceutical, and biotechnology companies.